$0.36
Aptose Biosciences is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.37 – an increase of 0.33% over the previous week. Aptose Biosciences employs 35 staff and has a market cap (total outstanding shares value) of 0.00.
What's in this guide?
Our top picks for where to buy Aptose Biosciences stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Aptose Biosciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – APTO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Aptose Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Aptose Biosciences stock price (NASDAQ: APTO)
Use our graph to track the performance of APTO stocks over time.Aptose Biosciences shares at a glance
Latest market close | $0.37 |
---|---|
52-week range | $0.33 - $3.32 |
50-day moving average | $0.41 |
200-day moving average | $1.14 |
Wall St. target price | $14.50 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-4.24 |
Is it a good time to buy Aptose Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aptose Biosciences price performance over time
Historical closes compared with the close of $0.3604 from 2024-10-15
1 week (2024-10-10) | -1.74% |
---|---|
1 month (2024-09-17) | -10.97% |
3 months (2024-07-17) | -45.80% |
6 months (2024-04-17) | -71.40% |
1 year (2023-10-17) | -86.08% |
---|---|
2 years (2022-10-17) | -33.77% |
3 years (2021-10-13) | 2.28 |
5 years (2019-10-17) | 1.975 |
Aptose Biosciences financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -136.29% |
Return on equity TTM | -694.13% |
Profit margin | 0% |
Book value | $-0.12 |
Market Capitalization | $6.9 million |
TTM: trailing 12 months
Aptose Biosciences share dividends
We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.
Have Aptose Biosciences's shares ever split?
Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.
Aptose Biosciences share price volatility
Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $0.33 up to $3.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.358. This would suggest that Aptose Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aptose Biosciences overview
Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.
Frequently asked questions
nullWhat percentage of Aptose Biosciences is owned by insiders or institutions?
Currently 17.11% of Aptose Biosciences shares are held by insiders and 15.077% by institutions. How many people work for Aptose Biosciences?
Latest data suggests 35 work at Aptose Biosciences. When does the fiscal year end for Aptose Biosciences?
Aptose Biosciences's fiscal year ends in December. Where is Aptose Biosciences based?
Aptose Biosciences's address is: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3 What is Aptose Biosciences's ISIN number?
Aptose Biosciences's international securities identification number is: CA03835T2002 What is Aptose Biosciences's CUSIP number?
Aptose Biosciences's Committee on Uniform Securities Identification Procedures number is: 453219107
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question